

SEROLOGICAL DETECTION OF CELIAC DISEASE AMONG CHILDREN IN DIYALA PROVINCE- IRAQ

Assis. Prof. Dr. Abdulrazak SH. Hasan *, Prof. Dr. Nadhim Gh. Noaman **, Assis. Prof. Dr. Mehdi SH. Al-Zuheiry ***, Shahad KH. Al-Qaisi ****

* Collge of Veterinary Med., Diyala University, **, *** College of Medicine, Diyala University, **** College of Education, Diyala University

Abstract

Background: celiac disease (CD) is an autoimmune disorder that is common in the general population. Early serological diagnosis of CD access to treatment and improves the patient's quality of life.

Objectives: to explore the rate of CD among clinically suspected children in using serological tests and to assess the validity of these markers for the diagnosis of CD.

Materials and methods: This case control study was conducted in Diyala province-Iraq during the period from September 2011 to April 2012 in Al-Batool Teaching Hospital for Maternity and Children. 156 children who were clinically suspected as having CD and 124 healthy children as control group were enrolled. The patient's age range was 1 month to 6 years and above. Information regarding age, sex, residence, family history, and clinical signs were collected in a special questionnaire. Commercially available serological kits for anti-gliadin IgA (AGA-IgA) and anti-tissue transglutaminase IgA (anti-tTG-IgA) antibodies (Aeskulisa, Germany) were used by ELISA technique. Data were statistically analyzed and P value less than 0.05 was considered significant.

Results: Based on the seropositivity of both anti-AGA IgA and anti-tTG IgA, 15 (9.6%) were considered CD patients. whereas, patients who had either anti-AGA IgA (16.7%) or anti-tTG IgA (14.7%) positive were considered as symptomatic non-CD patients. The results showed that the anti-AGA IgA seropositivity was highly significant ($P < 0.001$) in CD patients compared to symptomatic non-CD patients and control groups. Likewise, the anti-tTG IgA positivity was highly significant ($P < 0.001$) in CD patients compared to symptomatic non-CD patients and control groups. Both tests had similar sensitivity, but the anti-tTG IgA has higher specificity, accuracy, and positive predictive value.

Conclusion: Serum Anti-tTG IgA is a good marker for the diagnosis of CD among clinically suspected patients; however, for more accuracy both anti-tTG IgA and anti-AGA IgA can be used.

KEYWORDS: CELIAC DISEASE. ANTI-GLUTIN. ANTI-TRANSGLUTINASE.

1. INTRODUCTION

Celiac disease (CD) is regarded as an autoimmune disorder in genetically susceptible individuals, triggered by gluten and related prolamins and characterized by severe malabsorption and flat intestinal mucosa ^[1]. CD is one of the best-known autoimmune human leukocyte antigen-dependent disorders, that has a relatively increased prevalence in first-degree relatives ^[2,3].

The identification of CD is challenging because it can begin not only with diarrhea and weight loss but also with atypical gastrointestinal and extra-intestinal symptoms, or it could be completely symptomless ^[4,5]. The accuracy of serological diagnosis of CD has progressively increased with the development of highly reliable tests. Serum antibody assays may serve as a first-step diagnostic tool: immunoglobulin A tissue transglutaminase (IgA tTG), IgA endomysial antibody (IgA EMA), IgA anti gliadin antibody (IgA AGA), and IgG anti gliadin antibody (IgG AGA) offers the best diagnostic accuracy regardless the

patient's age. [6-8]. These tests usually have high sensitivity and specificity exceeding 95% with no evidence that a combination of tests was better than a single test using either the EMA IgA or tTG IgA. [9,10]. However, the positivity of these markers does not always correlate with mucosal appearance in the small intestine [4,11].

Following the application of simple serological tests for the diagnosis of CD, the prevalence of CD in Middle East, North Africa and India countries among low risk populations was found to be similar to that of Western countries, but it was higher in high risk populations ranging between 3 and 20% [12-15]. Thus, it has been suggested that in the developing countries, both serological screening in the general population and serological testing in groups at risk are necessary for an early identification of celiac patients [16,17].

2. MATERIAL AND METHODS

This case control study was conducted in Diyala province-Iraq during the period from September 2011 to April 2012 in Al-Batool Teaching Hospital for Maternity and Children. 156 children who were clinically suspected as having CD and 124 apparently healthy children as control group were enrolled. The patient's age range was 1 month to 6 years and above. Socio-demographic data including age, sex, residence, family history, and clinical signs were collected in a special questionnaire. For human privacy, the patient parent's consensus was taken. Commercially available serological kits for anti-gliadin IgA (AGA-IgA) and anti-tissue transglutaminase IgA (anti-tTG-IgA) antibodies (Aeskulisa, Germany) were used by Enzyme-Linked Immunosorbant Assay (ELISA) technique following the manufacturer's instructions. Statistical analysis was done through the computerized software, Statistical Package Social Sciences (SPSS) version 20 by using the Chi-square. P value less than 0.05 was considered significant.

3. RESULTS

For statistical comparison, children who had positive serum anti-AGA-IgA and anti-tTG-IgA were considered CD patients, and those who had one of these markers positive were considered as symptomatic non-CD patients. Table (1) showed the range, mean and standard deviation of the study groups. The statistical analyses showed that there were insignificant differences among the study groups.

Table (1) Range, mean and standard deviation among the study groups.

Age (ys)	Healthy control (n= 124)	Symptomatic Non-CD (n= 141)	Celiac disease (n= 15)	P value
Range	(0.1-7)	(0.1-14)	(0.1-12)	0.08 [NS]
Mean	1.6	3.2	4.0	
SD	1.99	3.81	3.78	
SE	0.41	0.32	0.98	

[NS]: insignificant

Results showed that the overall anti-AGA IgA seropositivity rate in suspected patients group was 16.7% , which was significantly higher compared to control group (P= 0.031). Furthermore, the anti-AGA IgA seropositivity was highly significant (P< 0.001) in CD patients compared to symptomatic non-CD patients and control groups, table (2).

Table (2): Antigliadin IgA seropositivity rate among study groups.

Study groups	Anti-gliadin IgA			P value
	No.	Positive	%	
Control group	124	0	0.0	0.031
Suspected patients group	156	26	16.7	

Control group	24	0	0.0	< 0.001
symptomatic patients non-CD	141	11	7.8	
Celiac patients group	15	15	100.0	

Table (3) showed that the median serum concentration of anti-AGA IgA in CD patients was highly significant ($P < 0.001$) when compared to both symptomatic non-CD patients and control groups, while there was insignificant difference ($P = 0.87$) between the symptomatic non-CD patients and control group.

Table (3): concentration of anti-gliadin IgA among study groups.

Anti-gliadin Concentration	Healthy control (n= 124)	Symptomatic Non-CD (n= 141)	Celiac disease (n= 15)	P value
Range	(0.095-5)	(0.07- 88)	(12-300)	< 0.001
Median	2.03	2.10	32.0	
Interquartile range	(1.6-2.65)	(1-3)	(15-52)	
Mean rank	20.1	15.0	32.0	

The overall seropositivity rate of anti-tTG IgA in suspected patients group was 14.7%. The results revealed that there was insignificant difference ($P=0.16$) between the suspected and control groups, but it was highly significant ($P < 0.001$) in CD patients compared to symptomatic non-CD patients and control groups, table (4).

Table (4): Anti-tTG IgA positivity rate among study group.

Study groups	Anti-transglutaminase IgA			P value
	No.	Positive	%	
Control group	124	5	4.8	0.16 [NS]
Suspected patients group	156	23	14.7	
Control group	24	1	4.2	< 0.001
Symptomatic patients (not celiac)	141	8	5.7	
Celiac patients group	15	15	100.0	

The median concentration of anti-tTG IgA in CD patients was highly significant ($P < 0.001$) when compared to control and symptomatic non-CD patients group, whereas there was insignificant difference between the symptomatic non-CD patients and control group ($P = 0.24$), table (5).

Table (5): concentration of anti-transglutaminase IgA among study groups.

Anti-transglutaminase	Healthy control (n= 124)	Symptomatic Not celiac (n= 141)	Celiac disease (n= 15)	P value
Range	(1-21)	(0.1 -304)	(20-302)	< 0.001
Median	2.50	2.80	150.0	
Interquartile range	(2.25-3.4)	(2.3-4.8)	(26-300)	
Mean rank	72.5	85.2	169	

Table (6) revealed that the anti-AGA IgA and anti-tTG IgA were equal in their sensitivity, but the anti-tTG IgA test had higher specificity, accuracy, and positive PV.

Table (6): Validity of anti-AGA IgA and anti-tTA IgA.

Test	Sensitivity	Specificity	Accuracy	Positive PV		Negative PV
				50%	90%	100%
Anti-AGA IgA	100.0	92.2	92.9	92.8	99.1	100.0
Anti-tTG IgA	100.0	94.3	94.9	94.6	99.4	100.0

4. DISCUSSION

The present study is the first one in Diyala province, and one of the few studies on CD in Iraq. It was designed to explore the CD among clinically suspected children depending on serological markers, the Anti-AGA IgA and Anti-tTG IgA and to assess the validity of these tests for the diagnosis of CD. It had been documented that the correct diagnosis of CD in environmentally deprived children is frequently hindered by the common presence of other causes for the classical CD symptoms; malnutrition, failure to thrive and frequent diarrhea [4,18]. In this regard, malnutrition was well documented among Iraqi children as consequences of long term wars and deterioration of infrastructures beside the high prevalence of diarrhea causing diseases [19].

In the present study, 9.6% of the clinically suspected children had both anti-AGA IgA and anti-tTG IgA antibodies positive, while 16.7% had anti-AGA IgA positive and 14.7% had anti-tTG IgA positive. These results clearly revealed that CD in our region is within the range in the Middle East, India and North Africa [12,14,15, 18, 20]. These results can be explained on the fact that wheat has been the major staple food in these regions for a long time and it is possible that the continuous and high level of exposure to wheat proteins has induced some degree of immune tolerance, leading to milder symptoms, which are misdiagnosed as irritable bowel syndrome or unexplained gastrointestinal disorders. Of note, there was accumulating evidence of substantial underdiagnosis of CD in health care settings, where several studies had suggested that as few as a quarter of patients are recognized [21-22].

Our results also document that the combination of anti-AGA IgA and anti-tTG IgA tests represent a good diagnostic tool to confirm CD in suspected children, as these tests are manifested by high sensitivity, specificity, accuracy, and positive predictive values. Similar results were obtained by others [14,23,24]. Over the past decade, the diagnostic accuracy of serology for CD has markedly increased with the development of highly sensitive and specific tests, which were found to be an important screening tools for detection of latent CD, as these markers has the ability to discover a high number of silent CD, which can be classified as potential CD [10,11, 25]. Thus, a mass screening studies using serological markers is recommended, as the early detection of these patients would result in significant improvement of quality of their lives [2].

The study concluded that CD in our region is more prevalent than expected, and may well be under diagnosed, the combination of of serum anti-AGA IgA and anti-tTG IgA tests are a good diagnostic markers to confirm CD in suspected cases.

5. REFERENCES

1. Evans, K.E.and Sanders, D.S. Celiac disease. *Gastroenterol. Clin. North Am.* 2012; 41(3):639-50.
2. Grover, R.; Puri, A.S.; Aggarwal, N.and Sakhuja, P. Familial prevalence among first-degree relatives of celiac disease in North India. *Dig. Liver Dis* . 2007 ; 39 (10) 903-7
3. Chomeili, B.; Aminzadeh, M.; Hardani, A.K.; Fathizadeh, P; Chomeili, P. and Azaran, A. Prevalence of celiac disease in siblings of Iranian patients with celiac disease. *Arq. Gastroenterol.* 2011 ;48(2):131-5.
4. Setty, M.; Hormaza, L. and Guandalini, S. Celiac disease: risk assessment, diagnosis, and monitoring. *Mol. Diagn. Ther.* 2008;12(5):289-98.
5. Volta, U, and Villanacci, V. Celiac disease: diagnostic criteria in progress. *Cell Mol. Immunol.* 2011;8(2):96-102.
6. Reddick, B.K.; Crowell, K. and Fu, B. Clinical inquiries: What blood tests help diagnose celiac disease? *J. Fam. Pract.*2006;55(12):1088-93.

7. Naiyer, A.J.; Hernandez, L.; Ciaccio, E.J.; Papadakis, K.; Manavalan, J.S.; Bhagat, G. and Green PH. Comparison of commercially available serologic kits for the detection of celiac disease. *J. Clin. Gastroenterol.* 2009 ;43(3):225-32.
8. Vermeersch, P.; Geboes, K.; Marien, G.; Hoffman, I.; Hiele, M. and Bossuyt, X. Serological diagnosis of celiac disease: Comparative analysis of different strategies. *Clin. Chem. Acta.* 2012; 413(21-22):1761-7.
9. Hill, I.D. What are the sensitivity and specificity of serologic tests for celiac disease? Do sensitivity and specificity vary in different populations? *Gastroenterology* 2005;128(4 Suppl 1):S25-32.
10. Giersiepen, K.; Lelgemann, M.; Stuhldreher, N.; Ronfani, L.; Husby, S.; Koletzko, S. and Korponay-Szaboo, I.R.; ESPGHAN Working Group on Coeliac Disease Diagnosis. Accuracy of diagnostic antibody tests for coeliac disease in children: summary of an evidence report. *J. Pediatr. Gastroenterol. Nutr.* 2012 ;54(2):229-41.
11. Ludvigsson, J.F.; Brandt, L.; and Montgomery, S.M. Symptoms and signs in individuals with serology positive for celiac disease but normal mucosa. *BMC Gastroenterol.* 2009 ;9:57.
12. Malekzadeh, R.; Sachdev, A. and Fahid, A. A. Coeliac disease in developing countries: Middle East, India and North Africa. *Best Pract. Res. Clin. Gastroenterol.* 2005;19(3):351-8.
13. Ben Hariz, M.; Kallel-Sellami, M.; Kallel, L.; Lahmer, A.; Halioui, S.; Bouraoui, S.; Laater, A.; Sliti, A.; Mahjoub, A.; Zouari, B.; Makni, S. and Maherzi A. Prevalence of celiac disease in Tunisia: mass-screening study in schoolchildren. *Eur. J. Gastroenterol. Hepatol.* 2007;19(8):687-94.
14. Ageep, A.K. Celiac disease in the Red Sea state of Sudan. *Trop. Gastroenterol.* 2012;33 (2) : 118 -22.
15. Sood, A.; Midha, V.; Sood, N.; Avasthi, G. and Sehgal, A. Prevalence of celiac disease among school children in Punjab, North India. *J. Gastroenterol. Hepatol.* 2006;21 (10): 1622-5.
16. Akbari, M.R.; Mohammadkhani, A.; Fakheri, H.; Javad Zahedi, M.; Shahbakhani, B.; Nouraei, M.; Sotoudeh, M.; Shakeri, R. and Malekzadeh, R. Screening of the adult population in Iran for coeliac disease: comparison of the tissue-transglutaminase antibody and anti-endomysial antibody tests. *Eur. J. Gastroenterol Hepatol.* 2006;18(11):1181-6.
17. Cataldo, F. and Montalto, G. Celiac disease in the developing countries: a new and challenging public health problem. *World J. Gastroenterol.* 2007;13(15):2153-9.
18. Modelli, I.C.; Gandolfi, L.; Almeida, R.C.; Araújo, G.M.; Picanço, M. A. and Pratesi, R. Serological screening for celiac disease in symptomatic 12 to 36 month-old children. *Arg. Gastroenterol.* 2010;47(1):61-5.
19. Yamada, S.; Fawzi, M.C.; Maskarinec, G.G. and Farmer, P.E. Casualties: narrative and images of the war on Iraq. *Int. J. Health Serv.* 2006;36(2):401-15.
20. Mohammed, I.M.; Karrar, Z.E. and El-Safi, S.H. Coeliac disease in Sudanese children with clinical features suggestive of the disease. *East Mediterr. Health J.* 2006;12(5):582-9.
21. Joned, R. and Sleet, S. Coeliac disease. *Brit. Med. J. (middle East)* 2009;338:105-8.
22. Tikkakoski, S.; Savilahti, E. and Kolho, N.K. Undiagnosed celiac disease and nutritional deficiencies in adults screened in primary health care. *Scand. J. Gastroenterol.* 2007; 42:60-6.
23. Baudon, J.J.; Johanet, C.; Absalon, Y.B.; Morgant, G.; Cabrol, S. and Mougnot, J.F. Diagnosing celiac disease: a comparison of human tissue transglutaminase antibodies with antigliadin and antiendomysium antibodies. *Arch. Pediatr. Adolesc. Med.* 2004; 158 (6) : 584-8.
24. Lagerqvist, C.; Dahlbom, I.; Hansson, T.; Jidell, E.; Juto, P.; Olcen, P.; Stenlund, H.; Hernell, O. and Ivarsson, A. Antigliadin immunoglobulin A best in finding celiac disease in children younger than 18 months of age. *J. Pediatr. Gastroenterol. Nutr.* 2008;47(4):428-35.
25. Reeves, G.E.; Squance, M.L.; Duggan, A.E.; Murugasu, R.R.; Wilson, R.J.; Wong, R.C.; Gibson, R.A.; Steele, R.H. and Pollock, W.K. Diagnostic accuracy of coeliac serological tests: a prospective study. *Eur. J. Gastroenterol. Hepatol.* 2006;18(5):493-501.



Address for correspondence:

Author: Assis. Prof. Dr. Mehdi SH. Al-Zuheiry. College of Education, Diyala University

E-mail: meh_sh2000@yahoo.com